Skip to main content
Premium Trial:

Request an Annual Quote

Change of Heart (Genes)

Verve Therapeutics, a biotech focused on using gene editing to treat cardiovascular disease, has launched with a $58.5 million investment led by Alphabet's venture capital division, GV, Reuters reports.

In a statement, the firm says it will be developing gene-editing therapies to treat coronary artery disease in adults. "Poor adherence, costs, side effects, limited access ... all these challenges have limited the impact existing heart medications like cholesterol-lowering statins have had," Sekar Kathiresan, a cardiologist and geneticist at Massachusetts General Hospital, who will take on the CEO spot in July, tells Reuters. "With our therapy, we could change the treatment paradigm for heart disease from chronic care, daily pills or monthly injections to a one-and-done approach."

According to Reuters, the firm says it will use the funds it raised to begin testing in animal models, though it notes that it would be years before Verve would be able to market therapies.

Other investors include Arch Venture Partners, F-Prime Capital, and Biomatics Capital, the firm adds.

The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.